ó ð£j52ã óâ•SSS.SSS.SSS./SSS.SSS.SS S./SS S.SS S.SS S./SS S.SSS.SSS./SSS.SSS.SSS./SSS.SSS.SSS.SSS./SSS.SSS.SSS./SSS.SSS.SSS./S.rg) zClinical pathsaN**Initial Assessment** Primary immunodeficiency is suspected in children presenting with: - Recurrent infections requiring intravenous antibiotics - Recurrent deep-seated infections - Chronic oral or cutaneous candidiasis - Chronic diarrhea with atypical features - Complications from live vaccines - Autoimmune disease or malignancy)ÚtitleÚcontentÚ DiagnosisaØ**Diagnostic Workup** 1. A detailed infection history is obtained (frequency, severity, type, response to treatment) 2. Serum immunoglobulin levels (IgG, IgA, IgM) are measured 3. Specific antibody responses are assessed 4. B and T cell enumeration and functional studies are performed 5. Molecular genetic testing is considered based on clinical phenotype 6. Referral to an immunologist is made for diagnosis confirmation and assessment of the degree of immunodeficiencyÚ Managementaò**Immunization Strategy** Vaccine approach depends on immunodeficiency category: - **Selective IgA deficiency**: All live-virus and inactivated vaccines are given as per standard schedule - **Major antibody deficiencies or SCID on immunoglobulin therapy**: Routine inactivated vaccines are avoided (except inactivated [[298|influenza]] vaccine); inactivated vaccines may be given as part of pre-therapy immunologic assessment - **Common variable immunodeficiency**: Annual inactivated influenza vaccine is given; meningococcal conjugate vaccine (MenACWY) is begun at 2 months of age due to splenic dysfunction and inadequate meningococcal antibody coverage in immunoglobulin replacement **Ongoing Management** Care is coordinated with an immunologist for: - Immunoglobulin replacement therapy decisions - Monitoring for complications (malignancy, autoimmunity, progressive organ involvement) - Gastrointestinal surveillance in conditions with known GI manifestations - Genetic counseling for family membersa**Initial Evaluation** Systematic pulmonary physical examination should be performed in all children with respiratory symptoms or suspected pulmonary disease. This includes assessment of work of breathing, auscultatory findings, and signs of respiratory distress.aø**Imaging and Diagnostic Studies** Imaging selection depends on clinical presentation: - Chest radiography for initial assessment of acute conditions and to evaluate for complications such as [[396|pneumothorax]] or pleural effusion - High-resolution computed tomography for detailed evaluation of parenchymal disease, air-trapping, and structural abnormalities - Soft tissue neck radiographs when pharyngeal narrowing is suspected - Flexible bronchoscopy to assess dynamic airway changes when indicatedaI**Monitoring in Chronic Disease** In severe forms of systemic disease affecting the lungs (such as mucopolysaccharidosis type I), polysomnography is suggested yearly; in milder forms (such as mucopolysaccharidosis type II), polysomnography every 3 to 5 years is recommended to assess for sleep-related respiratory complications.aâ**Initial Assessment** Systematic evaluation begins with detailed history including age of symptom onset, growth trajectory, pubertal development, family history of endocrine disorders, and nutritional intake. Physical examination documents growth parameters, pubertal staging, and signs of specific endocrine dysfunction. **Hyperglycemia in Extremely Low Birth Weight Infants** Infants with birth weight less than 1600 g receiving parenteral nutrition may develop hyperglycemia.zDTreatment decisions require assessment of pubertal progression rate.a"Insulin infusion should be considered as part of parenteral nutrition management when hyperglycemia occurs. **Nutritional Support in Critical Illness** Very low birth weight infants benefit from early trophic feeding prior to advancement to full enteral nutrition. Gastrointestinal priming strategies support tolerance of advancing feeds. In infants with congenital heart disease and [[246|growth failure]], enteral nutrition with appropriate energy density supports growth while managing cardiac status. **Pubertal Disorders** Central [[222|precocious puberty]] management may include gonadotropin-releasing hormone analogs. Consideration of psychological and social factors also guides treatment decisions. **Referral Considerations** Complex endocrine disorders, including intersex conditions, [[136|congenital adrenal hyperplasia]], and disorders of pubertal timing, warrant evaluation by a pediatric endocrinologist. Multidisciplinary management involving genetics, urology, psychology, and other specialties may be necessary for optimal outcomes.aä**Clinical evaluation** - Paroxysmal cough pattern and posttussive vomiting are assessed - [[151|Respiratory distress]], cyanosis, apnea, bradycardia, and poor feeding are monitored for in infants - Complications including [[150|pneumonia]], [[315|seizures]], and signs of secondary [[278|bacterial infection]] are evaluated - [[226|Sepsis]] in infants is distinguished by the paroxysmal cough pattern on examination - Auscultation of the chest is usually normal despite severe coughaä**Diagnosis and initial assessment** - Nasopharyngeal secretions are obtained for PCR or culture to confirm diagnosis - Complete blood count is performed; leukocytosis with absolute lymphocytosis is expected (though this may be absent in infants) - Chest radiograph is obtained; obliteration of cardiac borders or signs of [[150|pneumonia]] and atelectasis are sought - In infants, the characteristic inspiratory whoop may be absent and classic laboratory findings may not be presentzÔ**Infection control** - Pertussis is highly communicable during the catarrhal and early paroxysmal cough stages (approximately 4 weeks after onset) - Appropriate respiratory isolation precautions are implementedu¢**Initial Evaluation** The infant is assessed for signs of heart failure: failure to thrive, tachypnea, diaphoresis during feeding, hepatomegaly, and poor feeding tolerance. These symptoms typically emerge at 3–6 months of age in infants with large defects. Cardiac auscultation identifies a pansystolic murmur (which masks the first heart sound), and a thrill is palpated for. Small defects may produce no murmur.a¡**Diagnostic Confirmation** Echocardiography is the primary diagnostic modality. Apical four-chamber views are used for perimembranous defects and short-axis views for muscular defects. Color flow Doppler interrogation is performed, particularly for small muscular defects in the apical region. A chest radiograph is obtained to assess for cardiomegaly, left atrial enlargement, and increased pulmonary artery flow.u·**Management Strategy** **Small defects** (< 3 mm): Clinical observation is appropriate. No intervention is required in most cases, as spontaneous closure occurs in the majority. Follow-up echocardiography can be performed to document closure. **Large defects** (6–10 mm) with normal pulmonary vascular resistance and symptoms of heart failure: Surgical evaluation is warranted. Surgery is performed before age 2 years to prevent the development of pulmonary vascular obstructive disease. **Timing of intervention** depends on the clinical situation. Infants with symptoms of failure to thrive, significant tachypnea, and poor feeding at 3–6 months of age require correction at that time.uï**Initial Assessment and Emergency Management** When a greatly elevated leukocyte count is identified (particularly >100,000/μL with symptoms), this constitutes a medical emergency requiring immediate intervention to prevent leukostasis.u¾**Risk-Based Treatment Intensification** Treatment intensity is tailored based on risk stratification: - **Standard-risk patients** (age 2–10 years, WBC ≤50,000/mm³): standard chemotherapy regimens - **High-risk patients** (age <1 or >10 years, WBC >50,000/mm³, CNS/testicular involvement, slow early response, adverse cytogenetics): intensified chemotherapy - **Infant ALL** (age <1 year): more intensive chemotherapy than older childrenuÜ**Management of Leukostasis** If leukostasis is suspected (symptoms: hypoxemia, mental status changes), immediately initiate measures to reduce leukocyte count: - Chemotherapy: hydroxyurea (specific dosing not provided in passages) - Exchange transfusion - Leukopheresis **Induction Chemotherapy Phase** Remission-induction therapy is initiated following diagnosis confirmation. This phase is associated with: - Prolonged cytopenias lasting 3–5 weeks - Risk of infectious or hemorrhagic complications in 2–5% of patients during this period **Monitoring During Induction** Close surveillance is essential during the 3–5 week induction phase for early detection and management of infectious and hemorrhagic complications.zPrognosis and outcomez‹Monitoring for early response: blast clearance from peripheral blood by day 7 and from bone marrow by day 14 indicates favorable prognosis.u**Initial Assessment** 1. Point tenderness over the anterior talofibular ligament and calcaneofibular ligament is examined for 2. Passive inversion is tested—marked pain indicates ligament injury 3. Weight-bearing ability is assessed; most children can bear slight weightzHX-rays are obtained in skeletally immature athletes to exclude fracture.uÜ**Acute Phase (First 48–72 Hours)** - **Protection and immobilization**: An air splint, elastic wrap, or ankle stirrup brace is applied to support the ankle in a functional position (right angle) - **Rest**: Ambulation or exercise is allowed only if it causes no pain or swelling during activity or within 24 hours. Crutches and light weight-bearing are used if pain occurs - **Ice**: Applied directly to the ankle for 20 minutes every 2 hours for the first 48 hours - **Compression**: Elastic wrap or air splint provides compression - **Elevation**: The extremity is elevated to reduce swelling - **NSAIDs**: Included as part of the treatment regimen **Rehabilitation** - Functional rehabilitation begins as soon as possible - Focus is on edema control, range of motion, strengthening, and proprioceptive restoration - Weight-bearing progresses as tolerated - Formal physical therapy is arranged - A lace-up ankle brace is prescribed for ongoing support and prevention of recurrencea1. A detailed menstrual history is obtained: age at menarche, cycle length, duration of flow, volume of bleeding, and pattern of bleeding 2. Bleeding risk is screened for: history of easy bruising, nosebleeds, family history of bleeding disorders, and heavy bleeding in relativesa]3. Complete physical examination is performed, including vital signs, assessment for pallor or signs of [[349|anemia]], thyroid palpation, and pelvic examination as appropriate 4. Hemoglobin or hematocrit is measured **Further Investigation** Based on clinical findings, further testing may include: - Thyroid function tests if thyroid dysfunction is suspected - Coagulation studies if there is a personal or family history of bleeding disorder - Testing for sexually transmitted infections if intermenstrual bleeding or risk factors are present - Pelvic ultrasound if structural pathology is suspectedaS**Stratification and Management** | Clinical Scenario | Management | |---|---| | Mild bleeding, normal hemoglobin, no contraceptive need | Observation and reassurance | | Low hemoglobin level (with or without other signs of iron deficiency) | Iron supplementation | | Symptomatic anemia or actively bleeding | Hospitalization | **Pharmacologic Options** - **Nonsteroidal anti-inflammatory drugs**: Ibuprofen or naproxen are used to reduce menstrual flow - **Combined hormonal contraceptives**: Highly effective for reducing or eliminating abnormal bleeding when appropriate for the adolescent)ézé{é|é}é~éé€éN)ÚPARTS©óÚh/tmp/claude-0/-home-danvics-docker-quiz/c1e0577a-e42c-4a3d-b1ea-3edd61103a4e/scratchpad/mdm/b01_part6.pyÚrsÉðð ð(&ñ'ð ð#vñwð ð$+ñ,ð%!ðH ð(tñuð ð#KñLð ð$jñkðð" ð(hñið Ð"lÑmØ ð $ñ @ðð2 ð(FñGð ð#wñxð ð$CñDðð* ð(`ñað ð#|ñ}ð ð$MñNðð* ð(BñCð ð#SñTð ð$YñZð$ "ð/@ñAð;ðB ð(OñPð Ð"pÑqØ ð$Zñ[ðð4 ð(QñRà ð #<ñ =ð ð $Nñ Oðñ[H r